Clinical trial
An Exploratory Clinical Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT06978647 is registered in ClinicalTrials.gov with China Immunotech (Beijing) Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Clinical Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Diseases
- Lead sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- May 19, 2025
- Completion date
- May 19, 2027
- Enrollment
- 12 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome (aps), igg4-related diseases, inflammatory myopathy, rheumatoid arthritis (ra), sjogren's syndrome, systemic lupus erythematosus (sle), systemic sclerosis (ssc)